These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect. Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340 [TBL] [Abstract][Full Text] [Related]
23. Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group. Wolters EC; Horstink MW; Roos RA; Jansen EN Adv Neurol; 1993; 60():648-52. PubMed ID: 8420204 [No Abstract] [Full Text] [Related]
25. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A; Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734 [TBL] [Abstract][Full Text] [Related]
26. A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance. Cedarbaum JM; Hoey M; McDowell FH J Neurol Neurosurg Psychiatry; 1989 Feb; 52(2):207-12. PubMed ID: 2649640 [TBL] [Abstract][Full Text] [Related]
27. Low-dosage treatment in de novo patients with Parkinson's disease: a prospective study. van der Drift JH Adv Neurol; 1987; 45():529-34. PubMed ID: 3825731 [TBL] [Abstract][Full Text] [Related]
35. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Brannan T; Yahr MD Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264 [TBL] [Abstract][Full Text] [Related]
36. A double-blind study of bromocriptine and L-dopa in de novo Parkinson's disease. Short-term results. Riopelle RJ; Gawel MJ; Libman I; King DB; McLean DR; Paulseth R; Raphy B; Bouchard S Eur Neurol; 1988; 28 Suppl 1():11-4. PubMed ID: 3288477 [TBL] [Abstract][Full Text] [Related]
37. The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease. Weiner WJ; Factor SA; Sanchez-Ramos JR J Neurol Neurosurg Psychiatry; 1989 Jun; 52(6):732-5. PubMed ID: 2746265 [TBL] [Abstract][Full Text] [Related]
38. Double-blind evaluation of oral L-prolyl-Lleucyl-glycine amide in Parkinson's disease. Barbeau A; Roy M; Kastin AJ Can Med Assoc J; 1976 Jan; 114(2):120-2. PubMed ID: 3279 [TBL] [Abstract][Full Text] [Related]
39. [Piribedil in the treatment of Parkinson disease (author's transl)]. Nardini M; Sciannandrone R; Fieschi C; De Simone G Riv Patol Nerv Ment; 1975; 96(2):103-10. PubMed ID: 778998 [TBL] [Abstract][Full Text] [Related]